Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Carcinoma, Hepatocellular 3Liver Neoplasms 2Head and Neck Neoplasms 2Uterine Cervical Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Stage III Lung Non-Small Cell Cancer AJCC v7 1Lung Neoplasms 1Liver Cirrhosis 1Hypoxia 1Gliosarcoma 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Temozolomide 93Radiotherapy 66Bevacizumab 35Radiation 22Carmustine 21Erlotinib Hydrochloride 17Chemotherapy, Adjuvant 17Irinotecan 16Magnetic Resonance Spectroscopy 13Radiotherapy, Conformal 11O(6)-benzylguanine 11Surgical Procedures, Operative 10Radiotherapy, Intensity-Modulated 10sargramostim 9Sirolimus 9Imatinib Mesylate 9Carboplatin 9temsirolimus 8motexafin gadolinium 7Thalidomide 7Gene Expression Profiling 7aldesleukin 6Sorafenib 6Radiosurgery 6Immunohistochemistry 6Hydroxyurea 6Gefitinib 6Filgrastim 6Everolimus 6Etoposide 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Gliosarcoma × fluoromisonidazole × Clear all
NCT00902577 2019-04-08

MRI and PET/FMISO In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme

National Cancer Institute (NCI)

Phase 2 Completed
50 enrolled 16 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡